Ultralife Upgraded to Neutral on Backlog & Product Commercialization
Zacks Investment Research upgraded Ultralife Corp. (ULBI) to a Neutral rating, citing a record backlog, product commercialization, manufacturing improvements, and broader opportunities from vertical integration.
Why it matters — ULBI watchers would care because the upgrade points to strengthening operational fundamentals such as backlog growth and commercialization progress.